In the long-term follow-up, after 6 months and 1 year of treatment of Helicobacter pylori-associated gastroduodenopathies caused by nonsteroidal anti-inflammatory drugs in patients with osteoarthritis, a significant decrease in tumor necrosis factor-α and epidermal growth factor on the background of sAPO-1/Fas growth with additional inclusion in the treatment of rebamipide in comparison with anti-Helicobacter therapy was seen, which helped to reduce the recurrence of gastroduodenopathies. The gene discussed is TNF; the disease is osteoarthritis.